Abstract
Multiple myeloma (MM) is a clonal B-cell malignant neoplasm. In recent years, higtone deacetylase (HDAC) are dysregulated in MM, and MM patients with high expression of HDAC have significantly poorer prognostic outcomes. Acetylation of proteins influences a diverse range of cellular functions. Moreover, histone acetylation transferase (HAT) and HDAC keep the acetylation status of proteins in dynamic balance. Histone deacetylase inhibitors (HDACI) have emerged as a novel class of chemotherapeutics which are being evaluated in clinical trials. This review discusses the research progress of HDACI in therapy of MM in recent years. Key words: Histone acetyltransferases; Multiple myeloma; Therapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
